Telmisartan
- Generic Name
- Telmisartan
- Brand Names
- Actelsar Hct, Micardis, Micardis-hct, Pritor, Twynsta, Tolura, Kinzalmono (previously Telmisartan Boehringer Ingelheim Pharma KG), Telmisartan Teva Pharma, Telmisartan Actavis
- Drug Type
- Small Molecule
- Chemical Formula
- C33H30N4O2
- CAS Number
- 144701-48-4
- Unique Ingredient Identifier
- U5SYW473RQ
- Background
Telmisartan is an angiotensin II receptor antagonist (ARB) used in the management of hypertension. Generally, angiotensin II receptor blockers (ARBs) such as telmisartan bind to the angiotensin II type 1 (AT1) receptors with high affinity, causing inhibition of the action of angiotensin II on vascular smooth muscle, ultimately leading to a reduction in arterial blood pressure. Recent studies suggest that telmisartan may also have PPAR-gamma agonistic properties that could potentially confer beneficial metabolic effects.
- Indication
Used alone or in combination with other classes of antihypertensives for the treatment of hypertension. Also used in the treatment of diabetic nephropathy in hypertensive patients with type 2 diabetes mellitus, as well as the treatment of congestive heart failure (only in patients who cannot tolerate ACE inhibitors).
- Associated Conditions
- Cardiovascular Events, Diabetic Nephropathy, Heart Failure, Hypertension
Telmisartan in Combination with Cytotoxic Regimens in Platinum-Resistant Ovarian Cancer
- First Posted Date
- 2025-02-07
- Last Posted Date
- 2025-02-07
- Lead Sponsor
- Tyler J Curiel
- Target Recruit Count
- 33
- Registration Number
- NCT06815497
- Locations
- 🇺🇸
Dartmouth Hitchcock, Lebanon, New Hampshire, United States
A Randomized, Double-blind, Multi-center, Active-controlled, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy of THP-00101, THP-00102, and THP-00103 in Subjects With T2DM and Essential Hypertension
- Conditions
- Type 2 DiabetesHypertension
- Interventions
- First Posted Date
- 2024-10-18
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- THPharm Corp.
- Target Recruit Count
- 221
- Registration Number
- NCT06647745
- Locations
- 🇰🇷
The Catholic University of Korea, Yeouido ST. Mary's Hospital, Seoul, Korea, Republic of
🇹🇭Thammasat University Hospital, Pathumthani, Thailand
Efficacy and Safety of HB-1 for Panic Disorder
- Conditions
- Panic DisorderMental Illness
- Interventions
- First Posted Date
- 2024-07-03
- Last Posted Date
- 2025-03-05
- Lead Sponsor
- Honeybrains Biotech LLC
- Target Recruit Count
- 240
- Registration Number
- NCT06483789
- Locations
- 🇦🇺
East Sydney Doctors, Darlinghurst, New South Wales, Australia
🇦🇺Innovate Clinical Research, Waitara, New South Wales, Australia
🇦🇺NeuroCentrix, Carlton, Victoria, Australia
Efficacy and Safety of Telmisartan Compared With Losartan
- Conditions
- Diabetic NephropathiesHypertension
- Interventions
- First Posted Date
- 2024-05-28
- Last Posted Date
- 2024-05-28
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 98
- Registration Number
- NCT06431477
- Locations
- 🇰🇷
Severance Hospital, Seoul, Korea, Republic of
Telmisartan in Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- Other: Standard of Care Regimen
- First Posted Date
- 2023-12-13
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Tyler J Curiel
- Target Recruit Count
- 36
- Registration Number
- NCT06168487
- Locations
- 🇺🇸
Dartmouth Health, Lebanon, New Hampshire, United States
A Clinical Trial to Evaluate the Blood Pressure Control of Telmisartan or Losartan in Essential Hypertensive Patients With Metabolic Syndrome
- Conditions
- Essential HypertensionMetabolic Syndrome
- Interventions
- First Posted Date
- 2023-05-06
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 116
- Registration Number
- NCT05843162
Prevention of Paclitaxel-induced Neuropathic Pain in Patients With Planned Paclitaxel Chemotherapy (PrevTel)
- First Posted Date
- 2022-04-12
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- Dr. Frank Behrens
- Target Recruit Count
- 35
- Registration Number
- NCT05322889
- Locations
- 🇩🇪
Department of Haematology/Medical Onkology, University Hospital, Goethe-University Frankfurt, Frankfurt, Germany
A Bioequivalence Study Between Telmione 80 mg and Micardis 80 mg in Healthy Adult Volunteers
- Conditions
- Hypertension
- Interventions
- Drug: Telminone 80 mg
- First Posted Date
- 2022-02-03
- Last Posted Date
- 2022-03-02
- Lead Sponsor
- HK inno.N Corporation
- Target Recruit Count
- 46
- Registration Number
- NCT05223101
- Locations
- 🇰🇷
Chungbuk National University Hospital, Cheongju-si, Chungcheongbuk-do, Korea, Republic of
A Bioequivalence Study Between Telmione Plus 80/12.5mg and Micardis Plus 80/12.5 mg in Healthy Adult Volunteers
- Conditions
- Hypertension
- Interventions
- Drug: Telmione plus 80/12.5mg
- First Posted Date
- 2021-09-10
- Last Posted Date
- 2022-02-16
- Lead Sponsor
- HK inno.N Corporation
- Target Recruit Count
- 46
- Registration Number
- NCT05040880
- Locations
- 🇰🇷
Chungbuk National University Hospital, Cheongju-si, Chungcheongbuk-do, Korea, Republic of
Early Treatment of Vulnerable Individuals With Non-Severe SARS-CoV-2 Infection
- Conditions
- Covid19Covid19 Drug TreatmentSARS-CoV2 InfectionSevere Acute Respiratory Syndrome Coronavirus 2
- Interventions
- First Posted Date
- 2021-06-10
- Last Posted Date
- 2023-01-31
- Lead Sponsor
- ANRS, Emerging Infectious Diseases
- Target Recruit Count
- 600
- Registration Number
- NCT04920838
- Locations
- 🇬🇳
Centre de traitement des maladies à tendance épidémique de Gbessia, Conakry, Guinea
🇧🇫Centre Muraz/INSP, Bobo-Dioulasso, Burkina Faso
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.